Finasteride Tablet, Film Coated
Product Images NDC 68071-3417

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-3417). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3417 3)

Finasteride 5 mg tablets label from NuCare Pharmaceuticals, Inc. This prescription drug packaging displays the product name, strength (5 mg), and quantity (#30 tablets). It includes manufacturer and distributor details, lot number, NDC code, serial number, storage instructions, and a warning to keep out of reach of children. The label also advises to see the manufacturer's label for a full list of ingredients.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' depicting mean change from baseline symptom scores over four years. Two lines compare Finasteride and placebo groups, with Finasteride showing a steady decrease in symptom score, reaching around -3.5 by Year 4, while placebo scores remain near -1. Sample sizes for each group at each time point are indicated below the x-axis.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph showing the percent of patients having surgery for benign prostatic hyperplasia (BPH), including TURP, over 48 months. Two groups are compared: Finasteride and Placebo, with Placebo showing a higher cumulative percentage of surgeries than Finasteride. Below the graph, tables provide cumulative events and number of patients at risk per year for both groups.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' comparing Finasteride and placebo groups over a 48-month observation period. The y-axis represents the percent of patients (0-15%), and the x-axis is time in months (0-48). Two lines display cumulative patient percentages, with the placebo group showing a higher increase over time. Below the graph is cumulative event and at-risk patient data by year for both groups.*

FDA Label Image

Figure4 (Finasteride Fig4)

Figure 4 is a line graph showing prostate volume changes over four years in a long-term efficacy and safety study comparing Finasteride (5 mg tablet) to placebo. The y-axis represents mean percent change from baseline, with Finasteride showing a reduction in prostate volume over time, while placebo shows an increase. Sample sizes for each group at each year are indicated below the graph.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group.' The x-axis represents years from randomization (0 to 5.5 years), and the y-axis shows the percent with event (0 to 25%). Four lines display cumulative incidence for Placebo, Finasteride, Doxazosin, and Combination treatment groups, with Placebo having the highest cumulative incidence and Combination the lowest over time.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of Finasteride, depicting its steroid-related molecular framework with multiple ring systems and functional groups including keto and amide components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.